In the Phase 3 RELIANCE III study, the REL-1017 treatment arm showed a MADRS reduction of 14.8 points at Day 28 versus 13.9 points for the placebo arm, a higher than expected placebo response.

The Phase 3 Reliance II trial was designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder or MDD, to be used in combination with other approved anti-depressants.

Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder ValueCORAL GABLES, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq ...

CORAL GABLES, Fla., June 18, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today ...

(2024-12-09 | NDAQ:RLMD) Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017. Stockhouse.com uses cookies on this site. By continuing to use our service, you ...

CORAL GABLES, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the ...

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the publication of REL-1017 clinical data ...